Fortress Biotech Stock News

SCOTTSDALE, Ariz., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and

NEW YORK and SOLANA BEACH, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with suppor

Brokerages predict that Fortress Biotech, Inc. (NASDAQ:FBIO) will report sales of $29.93 million for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Fortress Biotechs earnings. The lowest sales estimate is $15.15 million and the highest is $75.52 million. Fortress Biotech posted sales of $13.75 million in the same quarter last [] The post $29.93 Million in Sales Expected for Fortress Biotech, Inc. (NASDAQ:FBIO) This Quarter appeared first on ETF Daily News .

Fortress Biotech Inc. (NASDAQ:FBIO) shares, rose in value on Friday, 11/26/21, with the stock price down by -5.03% to the previous days close as strong demand from buyers drove the stock to $2.83. Actively observing the price movement in the last trading, the stock closed the session at $2.98, falling within a range of $2.805 Fortress Biotech Inc. (NASDAQ:FBIO) Will Likely Reach 24.00 USD! Read More »

Prudential Financial Inc. grew its stake in shares of Fortress Biotech, Inc. (NASDAQ:FBIO) by 26.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 233,255 shares of the biopharmaceutical companys stock after buying an additional 48,300 shares during the period. Prudential Financial Inc.s holdings in Fortress Biotech were worth $833,000 as of its most recent []

B. Riley reissued their buy rating on shares of Fortress Biotech (NASDAQ:FBIO) in a research report released on Wednesday, Zacks.com reports. FBIO has been the topic of several other reports. Zacks Investment Research raised Fortress Biotech from a sell rating to a hold rating and set a $3.50 target price on the stock in a []

B. Riley reissued their buy rating on shares of Fortress Biotech (NASDAQ:FBIO) in a research report released on Wednesday morning, Zacks.com reports. FBIO has been the subject of several other research reports. Zacks Investment Research raised shares of Fortress Biotech from a sell rating to a hold rating and set a $3.50 price target for []

Wall Street analysts forecast that Fortress Biotech, Inc. (NASDAQ:FBIO) will post earnings per share (EPS) of ($0.09) for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Fortress Biotechs earnings, with the highest EPS estimate coming in at $0.09 and the lowest estimate coming in at ($0.15). Fortress Biotech posted []

Fortress Biotech (NASDAQ:FBIO) issued its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06), Fidelity Earnings reports. Fortress Biotech had a negative net margin of 63.05% and a negative return on equity of 15.34%. Shares of NASDAQ FBIO traded up $0.01 on []

SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and

SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (Journey Medical), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress), today announced the closing of its initial public offering of common stock of 3,520,000 shares at a public offering price of $10.00 per share, for gross proceeds of $35.2 million, before deducting underwriting discounts and offering expenses. All of the shares of common stock were offered by Journey Medical.

Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the Zacks consensus estimate of ($0.08) by ($0.06), Fidelity Earnings reports. Fortress Biotech had a negative net margin of 63.05% and a negative return on equity of 15.34%. NASDAQ:FBIO traded down $0.10 during trading hours []

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -225.00% and 14.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?